Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle cells by interferon-γ contributes to medial immunoprivilege

Journal of Immunology

Volumn 179, Issue 8, 2007, Pages 5246-5254

  Cuffy, Madison C ^a   Silverio, Amanda M ^a   Qin, Lingfeng ^a   Wang, Yinong ^a   Eid, Raymond ^a   Brandacher, Gerald ^b   Lakkis, Fadi G ^a,c   Fuchs, Dietmar ^b   Pober, Jordan S ^a   Tellides, George ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL TRYPTOPHAN; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; N METHYLTRYPTOPHAN; UNCLASSIFIED DRUG; 1-METHYL-TRYPTOPHAN; DRUG DERIVATIVE; GROWTH INHIBITOR; TRYPTOPHAN;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTICLE; CELL COMPARTMENTALIZATION; CELL LOSS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ENDOTHELIUM CELL; FEMALE; GRAFT ARTERIOSCLEROSIS; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MEDIAL IMMUNOPRIVILEGE; MEMORY CELL; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUNICA MEDIA; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL MOTION; COCULTURE; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME INDUCTION; ENZYMOLOGY; HELPER CELL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION; VASCULAR ENDOTHELIUM;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; COCULTURE TECHNIQUES; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; ENZYME INDUCTION; FEMALE; GROWTH INHIBITORS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; MUSCLE, SMOOTH, VASCULAR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; TRYPTOPHAN; TUNICA MEDIA;

EID: 38449083896     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.8.5246     Document Type: Article

References (51)

1. Billingham, M.E. 1987. Cardiac transplant atherosclerosis. Transplant. Proc. 19 (Suppl 5): 19-25.
2. Emeson, E. E., and A. L. Robertson, Jr. 1988. T lymphocytes in aortic and coronary intimas: their potential role in atherogenesis. Am. J. Pathol. 130: 369-376.
3. van der Wal, A. C., P. K. Das, D. Bentz van de Berg, C. M. van der Loos, and A. E. Becker. 1989. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab. Invest. 61: 166-170.
4. Salomon, R. N., C. C. Hughes, F. J. Schoen, D. D. Payne, J. S. Pober, and P. Libby. 1991. Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am. J. Pathol. 138: 791-798.
5. + T cells and production of interferon-γ- inducible chemokines in rejecting human arteries. Am. J. Transplant. 5: 1226-1236.
6. Galkina, E., A. Kadl, J. Sanders, D. Varughese, I. J. Sarembock, and K. Ley. 2006. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J. Exp. Med. 203: 1273-1282.
7. Wang, Y., W. R. Burns, P. C. Tang, T. Yi, J. S. Schechner, H. G. Zerwes, W. C. Sessa, M. I. Lorber, J. S. Pober, and G. Tellides. 2004. Interferon-γ plays a nonredundant role in mediating T cell-dependent outward vascular remodeling of allogeneic human coronary arteries. FASEB J. 18: 606-608.
8. Dal Canto, A. J., P. E. Swanson, A. K. O'Guin, S. H. Speck, and H. W. Virgin. 2001. IFN-γ action in the media of the great elastic arteries, a novel immunoprivileged site. J. Clin. Invest. 107:R15-R22.
9. Medawar, P. B. 1948. Immunity to homologous grafted skin, III: the fate of skin homografts transplanted to the brain and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29: 58-69.
10. Streilein, J. W. 2003. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3: 879-889.
11. Carson, M. J., J. M. Doose, B. Melchior, C. D. Schmid, and C. C. Ploix. 2006. CNS immune privilege: hiding in plain sight. Immunol. Rev. 213: 48-65.
12. Baban, B., P. Chandler, D. McCool, B. Marshall, D. H. Munn, and A. L. Mellor. 2004. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 61: 67-77.
13. Taylor, M. W., and G. S. Feng. 1991. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5: 2516-2522.
14. Munn, D. H., M. Zhou, J. T. Attwood, I. Bondarev, S. J. Conway, B. Marshall, C. Brown, and A. L. Mellor. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193.
15. Mellor, A. L., and D. H. Munn. 2003. Tryptophan catabolism and regulation of adaptive immunity. J. Immunol. 170: 5809-5813.
16. + T cell proliferation in vitro. J. Immunol. 154: 151-161.
17. Terness, P., T. M. Bauer, L. Rose, C. Dufter, A. Watzlik, H. Simon, and G. Opelz. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196: 447-457.
18. Frumento, G., R. Rotondo, M. Tonetti, G. Damonte, U. Benatti, and G. B. Ferrara. 2002. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med.196: 459-468.
19. Munn, D. H., E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine, and A. L. Mellor. 1999. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med.189: 1363-1372.
20. Hwu, P., M. X. Du, R. Lapointe, M. Do, M. W. Taylor, and H. A. Young. 2000. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164: 3596-3599.
21. Munn, D. H., M. D. Sharma, J. R. Lee, K. G. Jhaver, T. S. Johnson, D. B. Keskin, B. Marshall, P. Chandler, S. J. Antonia, R. Burgess, et al. 2002. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297: 1867-1870.
22. Terness, P., J. J. Chuang, T. Bauer, L. Jiga, and G. Opelz. 2005. Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood 105: 2480-2486.
23. Travers, M. T., I. F. Gow, M. C. Barber, J. Thomson, and D. B. Shennan. 2004. Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells. Biochim. Biophys. Acta1661: 106-112.
24. Seymour, R. L., V. Ganapathy, A. L. Mellor, and D. H. Munn. 2006. A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J. Leukocyte Biol. 80: 1320-1327.
25. Mellor, A. L., and D. H. Munn. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762-774.
26. Fleckner, J., P. M. Martensen, A. B. Tolstrup, N. O. Kjeldgaard, and J. Justesen. 1995. Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in cell lines. Cytokine 7: 70-77.
27. Munn, D. H., M. D. Sharma, B. Baban, H. P. Harding, Y. Zhang, D. Ron, and A. L. Mellor. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22: 633-642.
28. Sakash, J. B., G. I. Byrne, A. Lichtman, and P. Libby. 2002. Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydophila pneumoniae infection. Infect. Immun. 70: 3959-3961.
29. Daubener, W., B. Spors, C. Hucke, R. Adam, M. Stins, K. S. Kim, and H. Schroten. 2001. Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. Infect. Immun. 69: 6527-6531.
30. Schroten, H., B. Spors, C. Hucke, M. Stins, K. S. Kim, R. Adam, and W. Daubener. 2001. Potential role of human brain microvascular endothelial cells in the pathogenesis of brain abscess: inhibition of Staphylococcus aureus by activation of indoleamine 2,3-dioxygenase. Neuropediatrics 32: 206-210.
31. Adam, R., D. Russing, O. Adams, A. Ailyati, K. Sik Kim, H. Schroten, and W. Daubener. 2005. Role of human brain microvascular endothelial cells during central nervous system infection: significance of indoleamine 2,3-dioxygenase in antimicrobial defence and immunoregulation. Thromb. Haemostasis 94: 341-346.
32. Pantoja, L. G., R. D. Miller, J. A. Ramirez, R. E. Molestina, and J. T. Summersgill. 2000. Inhibition of Chlamydia pneumoniae replication in human aortic smooth muscle cells by γ interferon-induced indoleamine 2, 3-dioxygenase activity. Infect. Immun. 68: 6478-6481.
33. Beutelspacher, S. C., P. H. Tan, M. O. McClure, D. F. Larkin, R. I. Lechler, and A. J. George. 2006. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am. J. Transplant. 6: 1320-1330.
34. Alexander, A. M., M. Crawford, S. Bertera, W. A. Rudert, O. Takikawa, P. D. Robbins, and M. Trucco. 2002. Indoleamine 2,3-dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 51: 356-365.
35. Liu, H., L. Liu, B. S. Fletcher, and G. A. Visner. 2006. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am. J. Respir. Crit. Care Med. 173: 566-572.
36. Beutelspacher, S. C., R. Pillai, M. P. Watson, P. H. Tan, J. Tsang, M. O. McClure, A. J. George, and D. F. Larkin. 2006. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur. J. Immunol. 36: 690-700.
37. Wirleitner, B., V. Rudzite, G. Neurauter, C. Murr, U. Kalnins, A. Erglis, K. Trusinskis, and D. Fuchs. 2003. Immune activation and degradation of tryptophan in coronary heart disease. Eur. J. Clin. Invest. 33: 550-554.
38. Brandacher, G., F. Cakar, C. Winkler, S. Schneeberger, P. Obrist, C. Bosmuller, G. Werner-Felmayer, E. R. Werner, H. Bonatti, R. Margreiter, and D. Fuchs. 2007. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int. 71: 60-67.
39. Shiao, S. L., J. M. McNiff, and J. S. Pober. 2005. Memory T cells and their costimulators in human allograft injury. J. Immunol. 175: 4886-4896.
40. + direct allorecognition in graft rejection. J. Immunol. 173: 3027-3034.
41. + cells by murine brain microvessel endothelial cells and smooth muscle/pericytes. J. Immunol. 151: 38-47.
42. Swanson, B. J., D. C. Baiu, M. Sandor, Z. Fabry, and M. N. Hart. 2003. A small population of vasculitogenic T cells expands and has skewed T cell receptor usage after culture with syngeneic smooth muscle cells. J. Autoimmun. 20: 125-133.
43. Weck, K. E., A. J. Dal Canto, J. D. Gould, A. K. O'Guin, K. A. Roth, J. E. Saffitz, S. H. Speck, and H. W. Virgin. 1997. Murine γ-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-γ responsiveness: a new model for virus-induced vascular disease. Nat. Med. 3: 1346-1353.
44. Presti, R. M., J. L. Pollock, A. J. Dal Canto, A. K. O'Guin, and H. W. Virgin, IV. 1998. Interferon γ regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J. Exp. Med. 188: 577-588.
45. Bodaghi, B., O. Goureau, D. Zipeto, L. Laurent, J. L. Virelizier, and S. Michelson. 1999. Role of IFN-γ-induced indoleamine 2,3 dioxygenase and inducible nitric oxide synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells. J. Immunol. 162: 957-964.
46. Bieber, C. P., E. B. Stinson, N. E. Shumway, R. Payne, and J. Kosek. 1970. Cardiac transplantation in man, VII: cardiac allograft pathology. Circulation 41: 753-772.
47. Stewart, S., G. L. Winters, M. C. Fishbein, H. D. Tazelaar, J. Kobashigawa, J. Abrams, C. B. Andersen, A. Angelini, G. J. Berry, M. M. Burke, et al. 2005. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24: 1710-1720.
48. Racusen, L. C., K. Solez, R. B. Colvin, S. M. Bonsib, M. C. Castro, T. Cavallo, B. P. Croker, A. J. Demetris, C. B. Drachenberg, A. B. Fogo, et al. 1999. The Banff 97 working classification of renal allograft pathology. Kidney Int. 55: 713-723.
49. Weyand, C. M., and J. J. Goronzy. 2003. Medium- and large-vessel vasculitis. N. Engl. J. Med. 349: 160-169.
50. Burns, J. C., and M. P. Glode. 2004. Kawasaki syndrome. Lancet 364: 533-544.
51. Tellides, G., and J. S. Pober. 2007. Interferon-γ axis in graft arteriosclerosis. Circ. Res. 100: 622-632.